Biotechnology company Transposon Therapeutics announced on May 21 that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for an intervention developed to treat progressive supranuclear palsy (PSP), an FTD disorder that primarily affects movement. The designation was granted to TPN-101, an orally administered drug that targets LINE-1, a virus-like…

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced in May that the US Food and Drug Administration (FDA) has accepted its letter of intent to apply for the qualification of the protein neurofilament light (NfL) in blood as a biomarker for the early detection of approaching symptom onset in genetic FTD.…

Biopharmaceutical company Aprionoia Therapeutics announced that it has received an FDA Fast Track Designation for an imaging tracer used to diagnose progressive supranuclear palsy (PSP), an FTD disorder that primarily affects movement. Aprinoia is evaluating the safety and efficacy of APN-1607, a PET tracer that can visualize two types of tau protein that contribute to…

AFTD Board member Kristin Holloway shared her experiences as a care partner for her husband, Lee, in an article published by Self magazine on May 17. Holloway began noticing alarming changes to Lee’s behavior in May 2016, when he was in his mid-30s. He regularly arrived late, or not at all, to his job at…